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Abstract
Critical limb ischemia (CLI) is a terminal disease with high morbidity and healthcare costs due to limb loss. There
are no effective medical therapies for patients with CLI to prevent amputation. Cell-based therapies are currently
being investigated to address this unmet clinical need and have shown promising preliminary results. The pur-
pose of this study was to characterize the output of a point-of-care cell separator (MarrowStim P.A.D. Kit), cur-
rently under investigation for the treatment of CLI, and compare its output with Ficoll-based separation. The
outputs of the MarrowStim P.A.D. Kit and Ficoll separation were characterized using an automated hematology
analyzer, colony-forming unit (CFU) assays, and tubulogenesis assays. Hematology analysis indicated that the
MarrowStim P.A.D. Kit concentrated the total nucleated cells, mononuclear cells, and granulocytes compared
with baseline bone marrow aspirate. Cells collected were positive for VEGFR-2, CD3, CD14, CD34, CD45, CD56,
CD105, CD117, CD133, and Stro-1 antigen. CFU assays demonstrated that the MarrowStim P.A.D. Kit output a
signiﬁcantly greater number of mesenchymal stem cells and hematopoietic stem cells compared with cells out-
put by Ficoll separation. There was no signiﬁcant difference in the number of endothelial progenitor cells output
by the two separation techniques. Isolated cells from both techniques formed interconnected nodes and micro-
tubules in a three-dimensional cell culture assay. This information, along with data currently being collected in
large-scale clinical trials, will help instruct how different cellular fractions may affect the outcomes for CLI patients.
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Introduction
Critical limb ischemia (CLI) is a debilitating disease,
which can lead to limb loss and is associated with high
rates of morbidity and mortality. Treatment options
for patients with CLI include surgical bypass and endo-
vascular procedures. However, these treatment options
have not led to durable results for all patients.1 Further-
more, 20–40% of patients with CLI are not eligible for
traditional treatment due to the severity of their disease2
and amputation is often their only option due to severe
pain and/or tissue necrosis.3 Patients with no-option
CLI report have lower quality of life scores than patients
with cancer, chronic heart disease, and chronic kidney
disease.4 In patients who undergo a below-knee amputa-
tion, there is a 10% perioperative death rate and a
15% above-knee amputation rate within 1 year. After
2 years, there is a 30% death rate, 15% above-knee am-
putation rate, and a 15% contralateral limb amputation
rate.5 These unsatisfactory outcomes have motivated the
search for alternative approaches such as autologous cell
therapies, which are currently under investigation as a
potential treatment to address this unmet clinical need.
Bone marrow aspirate (BMA) has emerged as the
most common cell source utilized in clinical studies
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evaluating the treatment of CLI with cell therapy. There
has been debate regarding the cell types in BMA, which
potentially drive tissue revascularization and angiogen-
esis.6 Bone marrow contains a complex mixture of cells,
including hematopoietic stem cells, stromal stem cells,
and their progeny. It has been hypothesized that stem
cells play an important role in tissue regeneration ei-
ther by directly contributing to new tissue formation
or by acting as growth factor/cytokine delivery vehicles
that orchestrate regeneration.7,8 Endothelial progenitor
cells (EPCs) have also been explored as a cell source to
treat CLI.9 However, stem and progenitor cells consti-
tute a very small fraction of the total number of nucle-
ated cells in BMA.10 Theoretically, these small numbers
of stem and progenitor cells could divide, differentiate,
and regenerate the target organ after transplantation.11
It may also be possible that more mature cell types
drive the regeneration process. For example, mouse
models of CLI demonstrated that puriﬁed blood mono-
cyte populations were able to enhance angiogenesis.12,13
For the regeneration of complex tissues required in CLI,
it is likely that a mixture of cells and signals are required
to drive revascularization. Regardless of the cell types re-
quired, it is important that they be delivered in a volume
appropriate for therapy.
Cell concentration has been utilized in most cell ther-
apy approaches to treat CLI, to limit the volume injected
into the muscle, and to prevent injury to the surround-
ing tissue. The volume of BMA harvested for CLI studies
has ranged between 50 and 750mL of bone marrow
with a more recent emphasis on limiting the amount
of bone marrow drawn to reduce the risks of anemia
and heart failure.14 Several trials have used concentra-
tion devices and numerous trials have used Ficoll gradi-
ent centrifugation in a central laboratory.14 Although
Ficoll gradient centrifugation has been a reliable labora-
tory technique to isolate the cellular fraction from bone
marrow, it has several limitations for clinical use, includ-
ing long processing and operating times, requirements
for a hospital laboratory, requirements for multiple
manual processing steps, which could affect the sterility
of the product, and the need for multiple anesthesia or
patient procedures to harvest and deliver the cells.
Therefore, a system capable of delivering an equivalent
isolation of the cellular fraction at the point of care
would have the advantage of avoiding some of the lim-
itations of the Ficoll gradient centrifugation method.
The goal of this study was to characterize the output
of a device currently under investigation as a potential
therapy for CLI (Fig. 1) and compare it with the out-
put of Ficoll gradient centrifugation. Understanding
the composition of the constituents in cell therapies
will be important in furthering our understanding




BMA was collected from the iliac crest from healthy
ﬁnancially compensated subjects who qualiﬁed for
FIG. 1. Sixty milliliters of bone marrow aspirate
anticoagulated with Anticoagulant Citrate
Dextrose Solution, Solution A was loaded into the
concentration device (left). After centrifugation,
the bone marrow is separated into platelet-poor
plasma (PPP), concentrated bone marrow aspirate
(cBMA), and red blood cells (RBCs) (right).
FIG. 2. Percent mononuclear cell recovery in
the output of the MarrowStim P.A.D. Kit and Ficoll
separation. n = 5, *p < 0.05.
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blood donation as per AABB standards. Aspiration was
performed by Poietics-Cambrex (Gaithersburg, MD),
AllCells (Alameda, CA), and HemaCare (Van Nuys,
CA) under their Institutional Review Board approval.
The needle was repositioned during aspiration to max-
imize stem cell numbers and minimize dilution with
peripheral blood. The samples were shipped overnight
for testing.
Bone marrow processing
One hundred milliliters of BMA was collected from
each donor and combined with 20mL of heparin
(44 units/mL ﬁnal concentration). Sixty milliliters of
anticoagulated BMA was processed in the MarrowStim
device (Biomet Biologics, Warsaw, IN) following
the manufacturer’s instructions for use. Approximately
6mL of concentrated bone marrow aspirate (cBMA)
was obtained; 0.5mL of cBMA was used for complete
blood count (CBC) analysis. Methods for Ficoll-Paque
(GE Healthcare, Little Chalfont, United Kingdom) pro-
cessing were followed according to the manufacturer’s
instructions. Brieﬂy, 60mL of anticoagulated BMA
was diluted with 60mL of phosphate-buffered saline
(PBS; Invitrogen, Carlsbad, CA) +2% fetal bovine
serum (FBS; ATCC, Manassas, VA). Eight milliliters of
diluted BMA was layered on top of 4mL of Ficoll-
Paque in 15 separate conical tubes. Tubes were then
centrifuged at 400 g for 30min. After centrifugation,
the buffy coat layer was collected and pooled into a con-
ical tube and washed twice by diluting with PBS+2% FBS
and centrifuging at 300 g for 10min. Cells were ﬁnally
diluted in 6mL of PBS+2% FBS (same volume as Mar-
rowStim device) before CBC analysis.
Cell counts
CBCs were obtained using a hematology analyzer with
a ﬁve-part differential (Cell-Dyn Sapphire; Abbott Lab-
oratories, Dallas, TX; n = 5 donors). The differential
feature of the Cell-Dyn categorizes the cell population
in the marrow into one of the ﬁve mature white
blood cells (WBC) types (neutrophils, monocytes, lym-
phocytes, eosinophils, and basophils) based on cell size
and granularity. Addition of the monocytes and lym-
phocytes together gives the mononuclear cell (MNC)
fraction in the marrow.
A protocol shown to provide accurate cell counts
in platelet-rich plasma samples from whole blood
was used to acquire cell counts.15 In brief, counts
were taken in triplicate from samples placed on a
rocker (Ames Aliquot Mixer Model 4651; Ames Com-
pany, Elkhart, IN) for a minimum of 15min before
counting to allow for an even distribution of the cells
within the sample.
Flow cytometry
BMA and cBMA samples (n = 6 donors) were labeled as
per manufacturer’s instructions for CD105 (Abcam,
Cambridge, MA), VEGFR-2 (R&D Systems, Minneap-
olis, MN), and CD3, CD14, CD34, CD45, CD56,
CD117, CD133, and Stro-1 (BD Biosciences, San Jose,
CA). Labeled cells were washed with ﬂuorescence-
activated cell sorting (FACS) buffer (PBS solution con-
taining 0.5% bovine serum albumin and 0.1% sodium
azide), pelleted, and ﬁxed in 0.5% paraformaldehyde
and 0.1% sodium azide in PBS solution. Samples
were then analyzed using an FACSCalibur device
(BD Biosciences). Ten thousand events were acquired
and analyzed using commercially available software.
The concentration of labeled cells in each sample
was calculated by multiplying the percent detected
by the concentration of WBCs in that sample as
measured by the automated cell counting method
described above.
Colony-forming unit assays
For the colony-forming unit–ﬁbroblast (CFU-F) assay
(mesenchymal stem cells [MSCs]), 2.5· 105 MNCs
were plated in duplicate in six-well plates in Mesencult
media (Stem Cell Technologies, Vancouver, Canada).
Cultures were incubated at 37C, 5% CO2, for 14
days before being ﬁxed in 100% methanol and stained
with Giemsa staining solution (Sigma-Aldrich, St.
Louis, MO). Colonies were counted microscopically
at 50· magniﬁcation. Only colonies with >40 cells
were counted.
For the CFU-Hill assay (EPC), 5 · 106 MNCs were
plated onto six-well ﬁbronectin-coated plates (Corning,
Corning, NY) and incubated in a 37C, 5% CO2 incu-
bator. On day 2, nonadherent cells were collected and
plated onto 24-well ﬁbronectin-coated plates at 106
cells per well. Cultures were incubated for an additional
3 days before being ﬁxed with methanol (Sigma, St.
Louis, MO) and stained with Giemsa staining solution.
CFU-Hill colonies were deﬁned as a central core of
round cells with radiating, elongated spindle-like cells
at the periphery and were counted microscopically at
50· magniﬁcation.
For the CFU-granulocyte, erythrocyte, macrophage,
megakaryocyte (CFU-GEMM) assay (hematopoietic
stem cells), cells were prepared at 5·105 nucleated cells
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in PBS with 2% FBS. Then, 0.3mL of this cell solution was
added into 3mL of MethoCult methylcellulose-based
media (Stem Cell Technologies). After bubbles dissipated,
1.1mL of the cell–media solution was pipetted into 35-
mm Petri dishes (n= 2; Stem Cell Technologies). A
third Petri dish was ﬁlled with sterile water and left un-
covered. All three Petri dishes were placed in a 100-mm
Petri dish (Corning) and placed in an incubator at
37C, 5% CO2, in air for 14 days. Following the incuba-
tion, each dish was placed on a grid and colonies were
counted at 50· magniﬁcation. CFU-GEMM colonies
were deﬁned as a dense core of erythroid clusters and
recognizable granulocyte and macrophage cells at the
periphery.
Microtubule and node assay
MNCs were plated onto T-75 ﬂasks (Fisher Scientiﬁc,
Fairlawn, NJ) in Mesencult media and washed once
the next day before incubating in Mesencult media at
37C, 5% CO2. Cells were then harvested and seeded
onto a 24-well plate coated with Matrigel (BD Bioscien-
ces). Cells were cultured for 16 h and stained with calcein
AM (Corning) before photographing representative
areas and counting the nodes at 50· magniﬁcation.
Node counts were averaged between all images.
Statistical analysis
Data are presented as mean– standard deviation. Stat-
istical signiﬁcance between population means was
compared using Student’s t-test (a = 0.05).
Results
Hematology analyzer cell counts
CBC analysis was performed on baseline BMA, Ficoll-
puriﬁed marrow, and cBMA. Cellular components of
the marrow were categorized based on size and granu-
larity into one of the ﬁve mature WBC types on the
hematology analyzer (Table 1). Cells were concentrated
signiﬁcantly with the MarrowStim P.A.D. Kit com-
pared with the Ficoll method (Table 1). The Marrow-
Stim P.A.D. Kit provided an average of 233,000 cells/
lL or 1.4· 109 total nucleated cells. Of these cells,
26% were MNCs. The percent recovery of MNCs was
signiﬁcantly greater than the output of the MarrowStim
device compared with Ficoll separation ( p = 0.007;
Fig. 2). The standard Ficoll method did remove
more red blood cells compared with the concentration
device (Table 1).
Flow cytometry
There were no signiﬁcant changes in CD marker ex-
pression pre- or postprocessing (Table 2), except for
an increase in the VEGF receptor ( p = 0.04). Of the
CD markers analyzed, the marker for WBC (CD45)
was most prevalent. Due to the signiﬁcant increase in
cellular concentration, there was a signiﬁcant increase
in the concentration of cells that were antigen positive
for the markers tested.
CFU assays
The clonal capacity of the marrow aspirate cells after
processing with the MarrowStim P.A.D. Kit and Ficoll
separation was analyzed (Fig. 3). There were signiﬁ-
cantly greater numbers of CFU-Fs (MSCs; p= 0.033)
and CFU-GEMMs (myeloid progenitor cells; p= 0.026)
in the output of the MarrowStim P.A.D. Kit compared
with Ficoll separation (Fig. 3A, 3E). The CFU-F concen-
tration in the output of the MarrowStim P.A.D. Kit was
3274– 2159 CFU-Fs/mL. There was no signiﬁcant dif-
ference in the number of CFU-endothelial progenitor
cells (CFU-EPCs) in the output of the two systems
( p= 0.12; Fig. 3C). Representative photomicrographs
of CFU-F, CFU-EPC, and CFU-GEMM colonies are
shown in Figure 3B, D, and F, respectively.
Microtubule and node assay
Cells from the MarrowStim P.A.D. Kit and Ficoll sep-
aration rapidly formed microtubules and nodes within
Table 1. Comparison of CBC Analysis on BMA, Ficoll-Separated Marrow, and cBMA from the MarrowStim P.A.D. Kit (n55)
TNC (k/lL) MONO (k/lL) LYM (k/lL) NEU (k/lL) EOS (k/lL) BASO (k/lL) PLT (k/lL) RBC (M/lL)
Preparation
BMA 23 – 7 1 – 0 5 – 1 17 – 6 0 – 0 0.1 – 0.0 117 – 26 4 – 1
Ficoll 53 – 20 3 – 2 9 – 8 27 – 16 4 – 7 0.7 – 0.4 90 – 34 0 – 0
MarrowStim 233 – 61 10 – 2 51 – 11 160 – 49 11 – 16 1.2 – 0.6 753 – 233 3 – 2
Fold increase from BMA
Ficoll 2.3 2.4 3.9 1.6 N/A 10.6 0.8 0.03
MarrowStim 10 8.1 10.6 9.4 N/A 19.4 6.4 0.7
BASO, basophil; BMA, bonemarrow aspirate; CBC, complete blood count; cBMA, concentrated bonemarrow aspirate; EOS, eosinophil; LYM, lymphocyte;
MONO, monocyte; N/A, not available due to zero value in input BMA; NEU, neutrophil; PLT, platelet; RBC, red blood cell; TNC, total nucleated cells.
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Table 2. FACS Analysis on BMA and cBMA from the MarrowStim P.A.D. Kit (n56)
CD marker Function and cell type BMA (%) cBMA (%)
R1 gate Lymphocytes 17.4 – 6.6 20.5 – 3.5
R2 gate Monocytes 4.0 – 1.2 4.3 – 1.5
R3 gate Granulocytes 75.5 – 5.8 71.2 – 7.2
VEGFR-2 Tyrosine kinase receptor (endothelial cells and precursors) 5.6 – 1.8 7.5 – 3.2
CD3 Antigen receptor (T cells) 9.0 – 3.3 11.5 – 2.9
CD14 Surface glycoprotein (monocytes and macrophages) 5.4 – 2.5 4.8 – 3.3
CD34 Transmembrane glycoprotein (hematopoietic and endothelial progenitor cells) 0.9 – 1.0 1.0 – 0.6
CD45 Transmembrane protein tyrosine kinase (white blood cells and hematopoietic stem cells) 91.1 – 4.9 90.7 – 6.6
CD56 NCAM-1 (heparin-binding glycoprotein; T cells) 8.3 – 8.5 7.7 – 5.8
CD105 TGF-b receptor, endoglin (SH2; endothelial cells, monocytes, macrophages,
a subpopulation of hematopoietic stem cells, and cultured mesenchymal stem cells)
4.1 – 3.4 9.3 – 16.1
CD117 Tyrosine kinase receptor (hematopoietic stem cells, B cells, and T cells) 3.2 – 5.5 1.8 – 1.2
CD133 Trasmembrane protein (hematopoietic stem cells and endothelial cells) 0.2 – 0.1 0.2 – 0.1
Stro-1 Bone marrow stromal cells 0.8 – 0.6 1.1 – 0.6
There were no signiﬁcant differences between the BMA and the cBMA for all markers analyzed, except for the VEGFR-2 receptor ( p = 0.04).
FACS, ﬂuorescence-activated cell sorting; TGF-b, transforming growth factor-b.
FIG. 3. Colony-forming units in the output of the MarrowStim P.A.D. Kit and Ficoll processing, as well as
representative photomicrographs. Colony-forming unit–ﬁbroblast (CFU-F) (A, B), colony-forming unit–
endothelial progenitor cells (CFU-EPCs) (C, D), and colony-forming unit–granulocyte, erythrocyte, macrophage,
megakaryocyte (CFU-GEMM) (E, F). n = 5, *p < 0.05.
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16 h (Fig. 4). The number of nodes per image was not
statistically different when the same number of MNCs
from the MarrowStim P.A.D. Kit and Ficoll separation
were cultured on Matrigel (Fig. 4A). A representative
ﬂuorescent micrograph of the nodes from MNCs
from the MarrowStim P.A.D. Kit is shown in Figure 4B.
Discussion
The results of this study demonstrated that the Marrow-
Stim P.A.D. Kit could replace the time-consuming and
labor-intensive Ficoll separation technique and provide
for point-of-care processing of autologous cBMA. Speciﬁ-
cally, the total nucleated cells (TNCs) ( p= 4E7), MNCs
( p=3E7), and granulocytes ( p= 2E6) were signiﬁ-
cantly increased by theMarrowStim P.A.D. Kit compared
with Ficoll separation (Table 1 and Fig. 2). This concen-
tration effect was also conﬁrmed through analysis of cell
surface markers for key cell types in BMA and cBMA
(Table 2). Increases in the number of CFUs for MSCs,
EPCs, and hematopoietic progenitor cells demonstrated
that the MarrowStim P.A.D. Kit could concentrate rare
stem and progenitor cells in bonemarrow (Fig. 3). Finally,
cells isolated by the MarrowStim P.A.D. Kit formed
microtubules and formed interconnected nodes and
microtubules in a three-dimensional cell culture environ-
ment (Fig. 4).
These experiments demonstrated that the Marrow-
Stim P.A.D. Kit could concentrate both mature and
progenitor bone marrow cell types, which may play a
role in the revascularization process. Limitations in
this study include a relatively small sample number
(n = 5–7 donors depending on the experiment) and
no autologous therapies have yet been proven safe
and effective in the treatment of CLI. However, the
results of this study serve as a reference point as to
the cellular proﬁle in the output of the device currently
under investigation, which can be later used to evaluate
success or failure of trials and put into context of other
cell therapies for CLI.
The mechanism by which cells affect the revasculari-
zation process in CLI is still under investigation and
no cell therapy has yet proven safe and effective for the
treatment of CLI. Teams have begun to explore which
cell types in cBMA could affect the revascularization pro-
cess individually. Culture-expanded endothelial cells
have been explored as a potential cell source for CLI
due to their ability to differentiate into multiple somatic
cell types and their capacity to secrete proangiogenic fac-
tors.9 Culture-expanded MSCs from bone marrow,16 ad-
ipose tissue,17 and induced pluripotent stem cells18 have
all been explored in rodent studies to treat CLI. Ficoll
separation and other separators have been used to treat
rodent models of CLI. Due to the nature of the Marrow-
Stim P.A.D. Kit, which required 60mL of autologous
BMA per device, rodent studies were not possible with-
out using athymic animals. Removing the immune re-
sponse component of revascularization might result in
a very different response to cBMA from theMarrowStim
P.A.D. Kit and Ficoll separation. In the future, large an-
imal and human studies may instruct how autologous
cBMA affects the CLI disease process.
Several pre-clinical studies have suggested that mono-
cytes play a critical role in directing revascularization.12,13
Monocytes contributed to a small, but measurable,
FIG. 4. Characterization of cells’ ability to form nodes and microtubules after isolation from the MarrowStim
P.A.D. Kit and Ficoll separation. (A) Equal numbers of cells output from the MarrowStim P.A.D Kit and Ficoll
separation formed an average number of nodes that were not statistically different ( p > 0.05). (B)
Representative ﬂuorescent micrograph demonstrating that cells isolated by the MarrowStim separator form
nodes and microtubules in 16 h.
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fraction in the output in this study (10– 2%). Studies are
ongoing to correlate cell counts with clinical results in CLI
trials.19 Such information could enable a better under-
standing of the mechanism of action of cBMA in treating
CLI and provide general information for future regener-
ative medicine approaches that require vascularization.
One potential advantage of utilizing a BMA as a cell
source is that a variety of cell types are available to be
concentrated. In addition to MSCs, the cBMA in this
study contained EPCs and hematopoietic stem cells.
EPCs and hematopoietic stem cells can present human
leukocyte antigens,20,21 so these cells must be depleted
in an allogeneic live or cadaveric stem cell source.
While it is unclear what exact cell population is required
to treat CLI, EPCs and hematopoietic stem cells are crit-
ical for angiogenesis and vasculogenesis.22–25 In addi-
tion, MSCs and hematopoietic stem cells have been
shown to cross talk and create a stem cell niche that is
beneﬁcial for both stem cell types.26,27 Soluble factors re-
leased from one progenitor cell type to another have
been shown to be required for cell survival and prolifer-
ation of colonies.28 This cross talk between cell types
could play a role in the efﬁcacy of future cell therapies
and suggests that a stem cell milieu might be advanta-
geous over an isolated or puriﬁed cell population.
Concentrating bone marrow with a disposable de-
vice such as the MarrowStim P.A.D. Kit has several
pragmatic advantages over Ficoll separation and, if
ﬁrst proven safe and effective, could enable earlier
or concurrent intervention when treating CLI. In a
pilot study testing cBMA for the treatment of CLI,
cBMA was formed using Ficoll separation techniques
for the ﬁrst 14 patients, which required two proce-
dures (one for bone marrow harvest and one for cell
delivery). The MarrowStim P.A.D. Kit was used for
the next 15 patients to decrease procedure time and
allow patients to undergo a single procedure. Switch-
ing from Ficoll separation to the MarrowStim P.A.D.
Kit decreased the average procedure time from
527 – 39min to 114 – 19min.29 Signiﬁcantly, treat-
ment with the MarrowStim P.A.D. Kit does not pro-
hibit other options that might become necessary or
available in the future. A pivotal clinical trial is cur-
rently ongoing to evaluate the effectiveness of the
MarrowStim P.A.D. Kit to prevent or delay amputa-
tion in patients with CLI (http://clinicaltrials.gov/
ct2/show/NCT01049919). Additional studies are also
being designed to further explore the potential role of
the MarrowStim P.A.D. Kit in the peripheral arterial
disease/CLI patient population.
In conclusion, the MarrowStim P.A.D. Kit efﬁciently
concentrated cell types from BMA that may have a role
in inducing new vascularization in patients with CLI.
This disposable device was more efﬁcient at capturing
TNCs, MNCs, and granulocytes than using traditional
Ficoll separation techniques. CFU assays indicated that
rare stem and progenitor cells were captured and concen-
trated by the MarrowStim P.A.D. Kit. This preliminary
research will require conﬁrmation in a larger set of sam-
ples and correlation with clinical outcomes to determine
which cell type or types drive the potential of the Mar-
rowStim P.A.D. Kit to treat CLI. As cellular therapies
continue to emerge, it will be important to quantify the
source, type, and concentrations of cells used for a
given therapy. Standardization between the outcomes
of characterization methods is needed. Without a con-
sensus on stem cell characterization methods, it will be
challenging to draw conclusions between various clinical
studies. Research is ongoing to advance the results of this
study and correlate the cellular proﬁle of theMarrowStim
P.A.D. Kit and clinical success when treating CLI.
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